Welcome to our dedicated page for bli news (Ticker: bli), a resource for investors and traders seeking the latest updates and insights on bli stock.
Berkeley Lights, Inc. operates as a leading biotechnology company dedicated to providing cutting-edge technology solutions for single-cell manipulation. The company's innovative platform facilitates advancements in biopharma, diagnostics, and life science research. Berkeley Lights leverages its proprietary OptoSelect™ technology to enable precise control over biological processes at the single-cell level.
Headquartered in the United States, Berkeley Lights serves a global customer base, including leading pharmaceutical companies, research institutions, and diagnostics firms. The company's technology empowers researchers to discover new drugs, create better diagnostics, and develop innovative therapies.
One of the notable recent achievements of Berkeley Lights is the expansion of its platform capabilities, enhancing the efficiency and accuracy of single-cell analysis. The company has also formed strategic partnerships with key industry players to drive further innovation and market reach.
Financially, Berkeley Lights continues to show robust performance, with steady revenue growth and strategic investments in research and development. The company is committed to maintaining a strong financial position to support its mission of advancing human health through groundbreaking biotechnological solutions.
Current projects include the development of advanced cell therapy applications and expanding the use of their technology in various research and clinical settings. These projects highlight Berkeley Lights' commitment to pushing the boundaries of what's possible in biotechnology.
Overall, Berkeley Lights, Inc. stands at the forefront of biotechnology, offering unparalleled solutions for single-cell research and manipulation. The company's dedication to innovation and quality makes it a significant player in the life sciences sector.
Berkeley Lights, Inc. (Nasdaq: BLI) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2023, at 11:15 a.m. Pacific Time. The company's management will present and conduct a Q&A session during the event. A live and archived webcast will be available on the company's website. Berkeley Lights specializes in life sciences tools aimed at accelerating the development of biotherapeutics and cell-based products.
Berkeley Lights (Nasdaq: BLI) has announced a definitive agreement to acquire IsoPlexis (Nasdaq: ISO) in an all-stock transaction valued at $57.8 million. The merger aims to create PhenomeX, focusing on functional cell biology research tools. IsoPlexis shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share held. The combined entity expects $70 million in annual cost synergies by 2024, driving profitability and earlier breakeven at $150 million in revenue. The transaction is set to close in early 2023, subject to shareholder approvals.
Berkeley Lights announced the launch of its Opto Memory B Discovery Rabbit workflow, enhancing the Beacon platform's capability to discover unique antibodies. This new workflow allows the rapid generation of monoclonal antibodies from rabbit memory B cells, expanding the company's market opportunity. Customers can screen 15,000 to 60,000 single cells and recover high-quality antibody sequences efficiently. This advancement aims to simplify the discovery process while reducing costs and time compared to traditional methods.
Berkeley Lights, Inc. (Nasdaq: BLI) announced that Monash University in Australia has adopted its Beacon® system and Opto® Plasma B Discovery workflow for antibody discovery research. This partnership enhances the Monash Antibody Technology Facility's capabilities, enabling rapid screening and characterization of antibodies using advanced single B cell screening technologies. The adoption significantly accelerates the antibody discovery process, reducing timelines from traditional methods. Dr. Yue Geng emphasized the collaboration’s role in advancing therapeutic developments critical to market needs.
Berkeley Lights, Inc. (BLI) announced Q3 2022 financial results, reporting total revenue of $21.4 million, a 12% decline year-over-year but a 12% increase quarter-over-quarter. The company achieved a record recurring revenue of $7.0 million, up 48% year-over-year. Gross margin improved to 70.2%, compared to 63.4% in Q3 2021. However, the net loss widened to $21.6 million, reflecting operational challenges. The company maintains its guidance for 2022 revenue to be approximately in line with 2021 figures.
Berkeley Lights, a leader in digital cell biology, will host its 2022 Investor Day on November 18 at 9:00 a.m. ET in New York City and via webcast. The event will feature presentations from the executive team, concluding with a Q&A session. Attendees can register and find the agenda on the Investor Relations section of the company’s website. Berkeley Lights focuses on accelerating the development of biotherapeutics and offers advanced solutions for single-cell analysis. Expectations about the company’s growth are subject to risks and uncertainties.
Berkeley Lights, Inc. (Nasdaq: BLI) will report its financial results for the third quarter of 2022 after market close on November 8, 2022. They will host a conference call at 1:30 p.m. Pacific Time. The call will be accessible via their website and will also be available for replay afterward. Berkeley Lights focuses on digital cell biology, providing a platform for rapid development and commercialization of biotherapeutics, utilizing advanced automation systems and proprietary consumables.
Berkeley Lights, Inc. (BLI) announces participation in the Bioprocess International 2022 Conference from September 27-30 in Boston. The company will showcase its Beacon® optofluidic platform, which streamlines cell line development for biologics and vaccine candidates. Aurora Fabry-Wood will present on September 28, discussing methods to select top-performing clones. GSK Vaccines will also present on September 27 about implementing the Beacon technology for accelerated vaccine development. Berkeley Lights aims to enhance productivity and quality in biologics manufacturing through its innovative workflows.
Berkeley Lights, a leader in digital cell biology, has appointed Scott Chaplin as its new chief legal officer and corporate secretary, effective immediately. Chaplin brings over 25 years of experience from various legal roles in public companies, having previously served at Shield AI and Vista Outdoor. His responsibilities will encompass governance, compliance, and management of the company's intellectual property. This addition is expected to strengthen Berkeley Lights' leadership as it pursues its strategy to advance cell-based products for improved patient outcomes.
Berkeley Lights, Inc. (BLI) reported Q2 2022 revenues of $19.2 million, a slight decline of 1% year-over-year. Recurring revenue surged by 50% to $5.9 million, with a gross margin of 67%. The company initiated a strategic plan focused on achieving positive operating cash flow by early 2025, emphasizing R&D return on investment, enhanced commercial execution, and leadership development. Operating expenses rose to $38.5 million, leading to a net loss of $25.7 million. For 2022, Berkeley Lights anticipates revenue to align closely with 2021 levels.
FAQ
What is the market cap of bli (bli)?
What does Berkeley Lights, Inc. do?
Who are the customers of Berkeley Lights?
What is OptoSelect™ technology?
Has Berkeley Lights achieved any recent milestones?
What are Berkeley Lights' current projects?
How is Berkeley Lights performing financially?
Where is Berkeley Lights headquartered?
What impact does Berkeley Lights have on the biotechnology sector?
What is the significance of their technology in biopharma?
Who are some of Berkeley Lights' strategic partners?
